MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Appili Therapeutics Inc (TSX:APLI)

0.0150 UNCHANGED
Last Price Updated: 9:45 AM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 200
Open 0.0150
Bid (Size) 0.0150 (27,750)
Ask (Size) 0.0200 (2,690)
Prev. Close 0.0150
Today's Range 0.0150 - 0.0150
52wk Range 0.0100 - 0.0400
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Engages Spartan Capital as Lead Underwriter for Planned IPO
Via Investor Brand Network
Topics Initial Public Offering
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Invited to Submit Full Proposal for DoD-Funded Ovarian Cancer Diagnostic Study
Via Investor Brand Network

Performance

YTD
-25.0%
-25.0%
1 Month
-25.0%
-25.0%
3 Month
-40.0%
-40.0%
6 Month
N/A
N/A
1 Year
-57.1%
-57.1%

More News

Read More
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host July 22 Livestream on Autoimmune Therapeutics Subsidiary Adimune
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) CEO to Present at Wall Street Reporter’s NEXT SUPER STOCK Event June 26
Via Investor Brand Network
TinyGemsBreaks – Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
Via Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Appoints Evofem CEO Saundra Pelletier to Board of Directors
Via Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Terminates Acquisition Agreement with Appili Therapeutics
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights ADI-100 Developments in Weekly Update Featuring Leadership Team
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Mayo Clinic’s Dr. Charles Howe in May 2 Update on ADI-100™ Preclinical Study
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Gains IRB Approval for Endometriosis Diagnostic Study
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Regains Nasdaq Compliance, Hearing Canceled
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) to Host Appili CEO in April 4 Update Focused on Infectious Disease Innovation
Via Investor Brand Network
News headline image
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Highlights CaSe Platform Acquisition in Weekly Update Focused on Early Cancer Detection
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Acquires Patents for DNA Damage Detection in Cancer Prevention
Via Investor Brand Network
Topics Intellectual Property
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Provides Update on Appili Therapeutics Acquisition and Federal Funding Applications
Via Investor Brand Network
News headline image
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Provides Corporate Update, Announces Weekly Investor Series
Via Investor Brand Network
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Advances ADI-100 Autoimmune Therapy Toward Clinical Trials
Via Investor Brand Network
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Subsidiary Pearsanta Engages Lead Underwriter for Planned IPO
Via Investor Brand Network
Topics Initial Public Offering
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) to Host Fireside Chat on Feb. 21 to Discuss Key Corporate Developments
Via Investor Brand Network
Topics Initial Public Offering
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Explores IPO for Pearsanta to Advance Early Cancer Detection
Via Investor Brand Network
Topics Initial Public Offering
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Subsidiary Advances ADI-100 Gene Therapy Toward Human Trials
Via Investor Brand Network
News headline image
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
From Aditxt, Inc.
Via Business Wire
InvestorNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Updates Shareholders on Equity Issuance and Shift to Debt Financing Strategy
Via Investor Brand Network
News headline image
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
From Aditxt, Inc.
Via Business Wire
BioMedNewsBreaks — Aditxt Inc. (NASDAQ: ADTX) Acquisition of Appili Therapeutics Moves Forward with Overwhelming Shareholder Approval
Via Investor Brand Network

Frequently Asked Questions

Is Appili Therapeutics Inc publicly traded?
Yes, Appili Therapeutics Inc is publicly traded.
What exchange does Appili Therapeutics Inc trade on?
Appili Therapeutics Inc trades on the Toronto Stock Exchange
What is the ticker symbol for Appili Therapeutics Inc?
The ticker symbol for Appili Therapeutics Inc is APLI on the Toronto Stock Exchange
What is the current price of Appili Therapeutics Inc?
The current price of Appili Therapeutics Inc is 0.0150
When was Appili Therapeutics Inc last traded?
The last trade of Appili Therapeutics Inc was at 02/24/26 09:45 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story